Results 1 to 10 of about 12,523 (206)
Candida parapsilosis is becoming a predominant non-albicans cause of invasive candidiasis (IC). Echinocandins are the preferred choice for IC treatment and prophylaxis. Resistance to echinocandins in C.
Zhongju Chen, Minya Lu
exaly +4 more sources
Evolutionary accumulation of FKS 1 mutations from clinical echinocandin-resistant Candida auris
Introduction: Drug resistance to echinocandins, first-line drugs used to treat Candida auris infection, is rapidly emerging. However, the accumulation of mutations in genes other than FKS1 (before an isolate develops to resistance via FKS1 mutations ...
Sufei Tian, Hailong Li, Yunzhuo Chu
exaly +4 more sources
Echinocandin B is a natural product that possesses potent antifungal property against a wide array of fungi. This antifungal agent is produced by Emericella rugulosa. The biosynthetic genes of echinocandin B are physically organized in two gene clusters (
Vandana Kumari +3 more
doaj +2 more sources
Background Candida glabrata is an important cause of invasive candidiasis. Echinocandins are the first-line treatment of invasive candidiasis caused by C. glabrata.
Yi Li +15 more
doaj +2 more sources
Global analysis of the evolution and mechanism of echinocandin resistance in Candida glabrata. [PDF]
The evolution of drug resistance has a profound impact on human health. Candida glabrata is a leading human fungal pathogen that can rapidly evolve resistance to echinocandins, which target cell wall biosynthesis and are front-line therapeutics for ...
Sheena D Singh-Babak +9 more
doaj +3 more sources
Echinocandin Resistance in Candida [PDF]
Invasive fungal infections are an important infection concern for patients with underlying immunosuppression. Antifungal therapy is a critical component of patient care, but therapeutic choices are limited due to few drug classes. Antifungal resistance, especially among Candida species, aggravates the problem.
David S Perlin, Perlin David S
exaly +3 more sources
FDA-Approved Antibacterials and Echinocandins
Since 1955, a total of 12 peptide-based drugs with antimicrobial or antifungal properties have received approval from the Food and Drug Administration (FDA).
Othman Al Musaimi
doaj +4 more sources
Fungal infections cause significant mortality and morbidity worldwide, and the limited existing antifungal reservoir is further weakened by the emergence of strains resistant to echinocandins, a first line of antifungal therapy.
Rocio Garcia-Rubio +5 more
doaj +1 more source
Although considered effective treatment for many yeast fungi, the therapeutic efficacy of the echinocandin class of antifungals for invasive aspergillosis (IA) is limited.
Ana Camila Oliveira Souza +6 more
doaj +1 more source
Background and Objectives: Overtreatment with antifungal drugs is often observed. Antifungal stewardship (AFS) focuses on optimizing the treatment for invasive fungal diseases.
Rita Murri +11 more
doaj +1 more source

